GlassScriptPhysician profile
Anthony D Marcucci
NPI 1437174851
$13,728.61
in general payments reported to CMS, 2019-2025
53 companies · $2,186 in 2025
The $2,186 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,622 · 2020: $1,169 · 2021: $1,424 · 2022: $2,056 · 2023: $1,861 · 2024: $2,411 · 2025: $2,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,423 · Education: $34.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,422.76 |
| Education | $34.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,375.22 | 2019-2025 | |
| Novo Nordisk INC | $1,528.24 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,430.67 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $1,029.26 | 2019-2025 | |
| Lilly USA, LLC | $834.60 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $517.49 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $497.28 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $480.33 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $479.43 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $434.03 | 2019-2024 | Tradjenta, Jardiance, Synjardy |
| Amgen INC. | $399.73 | 2019-2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $382.01 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $371.76 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $289.84 | 2019-2023 | Proquad, Gardasil 9 |
| Shield Therapeutics INC | $246.71 | 2023-2025 | Accrufer |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Marcucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.